Serum adipocyte fatty acid-binding protein levels are independently associated with sarcopenic obesity

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SAT 697-707-Obesity Pathophysiology
Saturday, June 15, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SAT-701
Tae Nyun Kim*1, Jong Chul Won2 and Eun Ju Lee3
1Inje University College of Medicine, 2Inje University, Seoul, South Korea, 3Inje University
Objective Adipocyte fatty acid-binding protein (A-FABP) plays a key role in obesity-related insulin resistance, inflammation and atherosclerosis. Given insulin resistance and inflammation may be involved in the pathogenesis of sarcopenic obesity (SO), this study examined the association of SO with serum A-FABP levels in Korean adults.

 Study subject/measurements Two hundred ninety eight (male: 119, female: 179) adults aged 20 - 70 years were examined using dual X-ray absorptiometry and computed tomography (CT). Sarcopenia was defined as the appendicular skeletal muscle mass (ASM) divided by weight (%) of < 1 SD below the mean values of young adults in both sexes. Obesity was defined as visceral fat area (VFA) ≥ 100 cm2 using abdominal CT. Serum A-FABP levels were measured using an enzyme-linked immunosorbent assay.

 Results Serum A-FABP levels were higher in groups with SO compared to non-SO groups in both men and women. In the unadjusted model, serum A-FABP levels were positively associated with VFA and negatively associated with ASM/weight. Even after adjusting for possible confounding factors, including age, gender, BMI, blood pressure, lipid profile, HOMA-IR, hsCRP, IL-6, TNF-α, adiponectin, and leptin, ASM/weight was found to be independently and negatively associated with serum A-FABP levels (P = 0.013). In addition, multiple logistic regression analysis showed that increased serum levels of A-FABP were independently associated with the presence of SO.  

 Conclusion The present findings indicate that serum A-FABP levels may be valuable markers of the presence of SO.

Nothing to Disclose: TNK, JCW, EJL

*Please take note of The Endocrine Society's News Embargo Policy at